COVID19 - home | Infectious Diseases Data Observatory

Covid-19

i

Credit NIH

We host one of the largest international collections of clinical data related to COVID-19 with detailed individual patient data on more than 800,000 hospitalised individuals from over 1,200 institutions across over 60 countries. IDDO has facilitated the re-use of these data in 60 novel analyses to date.

COVID-19 data platform

IDDO collates, harmonises and shares COVID-19 clinical data. By contributing and accessing data on the platform, you can promote research that informs clinical practice and the public health response.

Contribute data to the platform

See how data are being used

Access data from the platform

Our work on COVID-19

The platform enables responsible use of data, allowing researchers to address clinically important questions and generate new evidence that reduces the impact of COVID-19. IDDO has developed partnerships and resources to accelerate the global response to COVID-19 and to support high-quality research.

Living systematic review

COVID-19 medical product quality reports

Read more about our COVID-19 partners

Purple cell infected with covid-19

Explore the COVID-19 Clinical Research Coalition, a global research response to COVID-19 driven by the needs of low-resource settings.

Novel Coronavirus SARS-CoV-2

COVID-19 Clinical Research Coalition

Explore our COVID-19 publications

Cov2 causes COVID-19 credit: NIH

News

Dr Joan Shepherd and Matt Brack

IDDO at CUGH: connecting with the global health community

Image of Dr James Watson

Dr James Watson

Dr James Watson becomes IDDO’s new Associate Director

Children laughing, India

Credit Rajat-Sarki, Unsplash

World Economic Forum blog on IDDO

IDDO infographic

IDDO’s latest newsletter is out

ASTMH President Danial Bausch and Professor Philippe Guerin

IDDO’s Director recognised as an ASTMH Distinguished International Fellow for 2022

Medics in PPE on COVID-19 ward

Credit: DNDi, Tygerberg Testing-COVID19

Incomplete reporting of COVID-19 disease severity criteria compromises meta-analysis

IDDO infographic

IDDO’s latest newsletter is out

IDDO at the Geneva Health Forum 4 May 2022

ANTICOV trial finds drug combination nitazoxanide + ciclesonide does not reduce risk of hospitalization in COVID-19 outpatients

School girls

Credit Jessica Lea, DFID

Applications open for RSTMH 2022 grant programme

ANTICOV: clinical trial for COVID-19 in low-resource settings to test a new combination treatment, fluoxetine and budesonide

covid19

IDDO to make its COVID-19 studies discoverable on the Vivli platform